Innovative Antibacterial Biomimetic Matrix Demonstrates Safety and Efficacy in Complex Surgical and Chronic Wounds

Introduction: Non-healing wounds affect over 10.5 million US patients, with healthcare costs estimated at $28-$97 billion1. Multidrug-resistant organisms (MDROs) significantly complicate acute and chronic wounds2. To address this issue, a biomimetic matrix (BMM) was developed to prevent infection and promote healing. This self-assembling peptide technology evades microbial resistance, supports tissue regrowth, and conforms to wounds.Methods:Preclinical – BMM’s efficacy against several bacterial and fungal pathogens was tested by standard time-kill assays. Efficacy against mature biofilms was evaluated in vitro and ex vivo (porcine skin). MRSA-inoculated murine wounds treated with BMM were assessed by microbiology. In a swine model of full-thickness excisional wounds, BMM’s healing efficacy was tested vs. silver and collagen products using the Tissue Analytics platform and histopathology. Clinical – In a prospective case series, patients with complex wounds of different etiologies, including postoperative wound dehiscence, diabetic foot ulcer (DFU), and venous leg ulcer (VLU), were selected to receive standard of care plus BMM weekly applications until complete closure, and monitored over a minimum of 5 weeks.Results:Preclinical – In vitro, BMM demonstrated bactericidal efficacy against ≥6 log10 CFU of PaO1 and MRSA as early as 5 minutes and eliminated ≥6 log10 CFU of Gram-positive and Gram-negative clinical isolates, as well as sporulating and non-sporulating fungi within 24 hours. Notably, BMM showed superior antibiofilm efficacy compared to antimicrobial wound products, eradicating mature PaO1 biofilms in pig skin explants with a single application. Rapid bioburden reduction was confirmed in MRSA-infected murine wounds. BMM-treated swine full-thickness excisional wounds showed greater closure rates and reduced inflammation compared to collagen and silver products, singularly achieving complete re-epithelialization with healthy granulation tissue repletion by day 14. Clinical – In the case series, complete closure was observed in all patients across diverse wound etiologies, including postoperative wound dehiscence, DFU, and VLU, after two BMM applications (2 weeks). No adverse events or wound recurrence were recorded.Discussion: BMM demonstrates broad-spectrum activity against MDROs and biofilms.  BMM shows re-epithelialization, granulation tissue formation, and inflammation resolution superior to silver and collagen dressings. Clinical outcomes validate rapid and sustained closure of complex surgical and chronic wounds, suggesting benefits in hard-to-heal wound management.References:1 Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023. 2 Ding X, Tang Q, Xu Z, et al. Challenges and innovations in treating chronic and acute wound infections. Burns Trauma. 2022.